Navigation Links
Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis

Majority of DVT Cases Treated in Single-Setting With Trellis-8 Catheter

From Bacchus Vascular, Reducing Patient Lytic Exposure, Bleeding

Complications and Treatment Cost

SANTA CLARA, Calif., March 6 /PRNewswire/ -- Bacchus Vascular Inc., a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and interventional cardiologists for the minimally invasive treatment of deep vein thrombosis (DVT) and other peripheral vascular disease, announced today that the Journal of Vascular Interventional Radiology (JVIR) has published a study comparing the clinical use of the Trellis-8 infusion catheter from Bacchus Vascular with conventional catheter-directed thrombolysis (CDT) in the treatment of DVT in its March 2008 issue.

Results of the study showed that Grade II and III lysis was achieved in 93% of patients treated with the Trellis catheter and 79% of patients treated with CDT even though thrombolytic doses and infusion durations were less with the Trellis catheter than with conventional CDT. Major hemorrhage was reported in none of the Trellis catheter patients and in 8.5% of patients treated with CDT. The per-patient cost of therapy was $3,697 for the Trellis catheter and $5,473 for CDT. This cost reduction is due to approximately 80% of the Trellis catheter patients being treated in the single-setting of the interventional suite with less time required for follow-up monitoring in a costly critical care unit compared with CDT patients.

The study, which was authored by Daniel E. Hilleman, PharmD (Department of Pharmacy Practice, Creighton University School of Pharmacy, Omaha, NE) and Mahmood K. Razavi, MD (Department of Vascular and Interventional Radiology, Stanford University Hospital, Stanford, CA), compared retrospectively collected data from 147 patients treated for DVT with the Trellis-8 infusion catheter at 45 hospitals in the U.S. and three hospitals outside the U.S. with a meta-analysis of 14 published studies in the medical literature in which CDT was performed on a minimum of 15 patients with DVT.

"We are gratified to see this rigorously-analyzed comparative data published in a major medical journal," stated Scott Cramer, President and CEO of Bacchus Vascular. "We continue to believe in both the strong clinical and economic utility of the Trellis infusion catheter as recognition increases in the medical community of the benefit of early DVT intervention in combating post-thrombotic syndrome and potential future DVT events."

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit

SOURCE Bacchus Vascular Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
2. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
3. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
4. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
5. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
6. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
7. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
8. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
9. AMTs Lead Product Poised to Address Major Liver Disease
10. SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application
11. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
Post Your Comments:
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):